Incretin therapy

From W8MD weight loss and sleep centers

Incretin therapy for weight loss, obesity medicine, type 2 diabetes, GLP-1 medications, GIP therapies, DPP-4 inhibitors, and W8MD medical weight loss care

Incretin therapy


Specialty Obesity medicine, endocrinology, medical weight loss, diabetes medicine
Uses Obesity, overweight, weight loss, type 2 diabetes, insulin resistance, metabolic syndrome, sleep apnea






Related GLP-1, GIP, incretin mimetic, GLP-1 weight loss, W8MD Weight Loss, Sleep and MedSpa
File:Confused.jpge
Confused woman - W8MD can help.
Modern incretin therapy has transformed physician-supervised weight loss and obesity medicine.
Incretin medications may reduce appetite, increase satiety, and help eligible patients lose weight when combined with nutrition and follow-up care.
W8MD Weight Loss, Sleep and MedSpa can help eligible patients with incretin-based medical weight loss, including GLP-1 weight loss injections.
Meal replacements may support incretin therapy by improving protein intake, portion control, and long-term weight loss maintenance.
Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

Incretin therapy refers to medications that mimic, enhance, or extend the effects of natural gut-derived hormones called incretins. These hormones, especially glucagon-like peptide-1 or GLP-1 and glucose-dependent insulinotropic polypeptide or GIP, help regulate appetite, blood sugar, insulin secretion, glucagon secretion, gastric emptying, satiety, and body weight.

Incretin-based medications are widely used for type 2 diabetes and are now central to modern obesity medicine and medical weight loss. For many patients, the most important use of incretin therapy is weight loss, appetite control, GLP-1 maintenance therapy, and reduction of weight-related complications such as prediabetes, metabolic syndrome, fatty liver disease, hypertension, and sleep apnea. Diabetes treatment remains an important second use, especially in patients with type 2 diabetes, insulin resistance, and elevated hemoglobin A1c.

W8MD Weight Loss, Sleep and MedSpa can help eligible patients use incretin therapy safely and effectively as part of physician-supervised medical weight loss. W8MD offers GLP-1 weight loss injections, newer oral incretin options when appropriate, nutrition support, meal replacements, low-carbohydrate diet planning, sleep apnea screening, and long-term weight loss maintenance.

Overview

Incretin therapy includes two major medication categories:

For weight loss, the most powerful incretin therapies are GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists, and newer oral GLP-1 medications. For diabetes, both GLP-1-based medications and DPP-4 inhibitors may help lower blood sugar, although DPP-4 inhibitors usually produce much less weight loss.

What are incretins?

Incretins are gut hormones released after eating. They help the body coordinate digestion, insulin secretion, appetite, and nutrient handling.

Important incretin-related hormones include:

The two best-known incretins are GLP-1 and GIP.

GLP-1

GLP-1 is released from intestinal L cells after meals. It helps:

  • Stimulate glucose-dependent insulin secretion
  • Reduce inappropriate glucagon secretion
  • Slow gastric emptying
  • Increase satiety
  • Reduce appetite
  • Improve post-meal blood sugar
  • Support weight loss in pharmacologic doses

GIP

GIP is another incretin hormone released after eating. It influences insulin secretion, fat metabolism, and energy balance. Tirzepatide targets both GIP and GLP-1 receptors.

Mechanism of action

Incretin therapies may work through several mechanisms:

  • Increased glucose-dependent insulin secretion
  • Reduced glucagon secretion when glucose is elevated
  • Slowed stomach emptying
  • Increased fullness
  • Reduced appetite
  • Reduced food noise
  • Reduced calorie intake
  • Improved blood sugar after meals
  • Improved insulin sensitivity indirectly through weight loss
  • Improved cardiometabolic risk factors in selected patients

Because incretin medications act on appetite and satiety pathways, they can help patients who struggle with hunger, cravings, portion control, and repeated weight regain.

Incretin therapy for weight loss

Incretin therapy has become one of the most important developments in modern medical weight loss. For eligible patients with obesity or overweight with weight-related medical conditions, incretin medications may help produce clinically meaningful weight loss when used with nutrition, physical activity, sleep optimization, and long-term follow-up.

Weight-loss benefits may include:

  • Reduced hunger
  • Reduced cravings
  • Reduced food noise
  • Smaller meal size
  • Improved satiety
  • Improved adherence to diet plans
  • Improved blood pressure in some patients
  • Improved blood sugar in some patients
  • Improved triglycerides in some patients
  • Improved sleep apnea severity in selected patients
  • Improved long-term maintenance when continued and monitored

The FDA approved Zepbound or tirzepatide for chronic weight management in adults with obesity or overweight with at least one weight-related condition, in addition to reduced-calorie diet and increased physical activity.FDA Approves New Medication for Chronic Weight Management(link). U.S. Food and Drug Administration.November 8, 2023.

The FDA approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight(link). U.S. Food and Drug Administration.March 8, 2024.

Incretin therapy for type 2 diabetes

Incretin therapy was first widely used for type 2 diabetes. In diabetes care, incretin medications can lower blood sugar by increasing glucose-dependent insulin secretion and reducing glucagon levels when blood glucose is elevated.

Diabetes benefits may include:

  • Lower fasting blood sugar
  • Lower post-meal blood sugar
  • Lower hemoglobin A1c
  • Reduced need for some diabetes medications in selected patients
  • Weight loss with GLP-1 and related therapies
  • Cardiovascular benefit with selected GLP-1 medications

DPP-4 inhibitors are mainly diabetes medications and are generally weight-neutral, while GLP-1 receptor agonists and related incretin mimetics often produce weight loss.

Types of incretin therapy

GLP-1 receptor agonists

GLP-1 receptor agonists, also called incretin mimetics, are medications that directly activate GLP-1 receptors. They are used for type 2 diabetes, obesity, overweight, and selected cardiovascular or sleep apnea indications depending on the medication.

Examples include:

Dual GIP and GLP-1 receptor agonists

Dual incretin medications activate more than one incretin pathway. The best-known example is tirzepatide, which activates GIP and GLP-1 receptors.

Examples include:

Mounjaro is used for type 2 diabetes, while Zepbound is used for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. The FDA approved Zepbound as the first medication for moderate-to-severe OSA in adults with obesity.FDA Approves First Medication for Obstructive Sleep Apnea(link). U.S. Food and Drug Administration.December 20, 2024.

Oral GLP-1 receptor agonists

Some incretin therapies are oral medications rather than injections.

Examples include:

The FDA approved Foundayo or orforglipron in 2026 to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight and at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity.Novel Drug Approvals for 2026(link). U.S. Food and Drug Administration.

FDA labeling describes Foundayo as orforglipron tablets for oral use with initial U.S. approval in 2026.FOUNDAYO orforglipron tablets prescribing information(link). U.S. Food and Drug Administration.

DPP-4 inhibitors

DPP-4 inhibitors, also called incretin enhancers, block the enzyme dipeptidyl peptidase-4, which normally breaks down endogenous GLP-1 and GIP. By inhibiting DPP-4, these medications prolong natural incretin activity and help manage blood sugar after meals.

Examples include:

DPP-4 inhibitors are generally used for type 2 diabetes rather than weight loss. They are usually weight-neutral and do not produce the substantial weight loss seen with modern GLP-1 and GIP/GLP-1 medications.

A cardiovascular safety review notes that concerns have been raised about heart failure hospitalization with some DPP-4 inhibitors, especially saxagliptin, and that this may not be a uniform class effect."Cardiovascular safety of dipeptidyl peptidase-4 inhibitors".Current Cardiology Reports.2016;PMC:4891459.

Comparison of incretin therapies

Medication class Examples Main use Weight-loss effect Route
GLP-1 receptor agonists Semaglutide, liraglutide, dulaglutide Weight loss, type 2 diabetes, selected cardiovascular indications Moderate to substantial, depending on medication and dose Injection or oral for selected products
Dual GIP/GLP-1 receptor agonists Tirzepatide Weight loss, type 2 diabetes, sleep apnea indication for Zepbound Substantial in eligible patients Injection
Oral GLP-1 receptor agonists Rybelsus, Foundayo, orforglipron Diabetes or weight loss depending on product Variable; newer oral obesity products may produce clinically meaningful weight loss Oral tablet
DPP-4 inhibitors Sitagliptin, saxagliptin, linagliptin, alogliptin Type 2 diabetes Usually weight-neutral Oral tablet
Triple receptor agonists Retatrutide Investigational obesity and metabolic disease research Investigational; substantial weight reduction reported in phase 2 obesity trial Injection in studies

Approved incretin medications used in weight loss

Semaglutide

Semaglutide is a GLP-1 receptor agonist used in products such as Wegovy, Ozempic, and Rybelsus. Wegovy is used for chronic weight management and selected cardiovascular risk-reduction indications. Ozempic and Rybelsus are primarily diabetes products.

Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist used in Mounjaro and Zepbound. Mounjaro is used for type 2 diabetes. Zepbound is used for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity.

Liraglutide

Liraglutide is a daily GLP-1 receptor agonist. Saxenda is used for chronic weight management, while Victoza is used for type 2 diabetes.

Orforglipron

Orforglipron, marketed as Foundayo, is an oral small-molecule GLP-1 receptor agonist approved for adults with obesity or overweight with weight-related medical conditions. It is used with reduced-calorie diet and increased physical activity.FOUNDAYO orforglipron tablets prescribing information(link). U.S. Food and Drug Administration.

Emerging and investigational incretin drugs

Retatrutide

Retatrutide is an investigational triple-hormone-receptor agonist that targets GIP, GLP-1, and glucagon receptors. A phase 2 trial published in the New England Journal of Medicine reported that retatrutide produced substantial weight reduction in adults with obesity over 48 weeks."Triple-Hormone-Receptor Agonist Retatrutide for Obesity".New England Journal of Medicine.2023;doi:10.1056/NEJMoa2301972.PMID:37366315.

Retatrutide remains investigational unless and until approved by regulatory authorities for a specific indication. Patients should not buy research peptides or unapproved retatrutide products online.

CagriSema

CagriSema is an investigational combination of cagrilintide and semaglutide. Cagrilintide is an amylin analog, while semaglutide is a GLP-1 receptor agonist. This combination is being studied for obesity and metabolic disease.

Amycretin

Amycretin is an investigational medication designed to target both amylin and GLP-1 pathways. It is being studied as a potential obesity therapy.

Other incretin combinations

Future incretin therapies may combine GLP-1, GIP, glucagon, amylin, and other appetite or energy-balance pathways. These drugs may expand options for obesity medicine, diabetes care, and long-term maintenance.

Metabolic and cardiovascular benefits

Some incretin therapies provide benefits beyond weight loss and blood sugar control. Benefits may include:

The FDA cardiovascular indication for Wegovy is important because it recognizes that selected GLP-1 therapy may reduce major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight(link). U.S. Food and Drug Administration.March 8, 2024.

Side effects

Common side effects of GLP-1 and related incretin therapies include:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Abdominal discomfort
  • Bloating
  • Heartburn
  • Reduced appetite
  • Fatigue in some patients
  • Injection-site reactions for injectable products

These side effects are often more common when starting therapy or increasing the dose. Eating smaller meals, avoiding greasy foods, staying hydrated, and dose adjustment under medical supervision may help.

Safety considerations

Incretin medications require medical supervision. They may not be appropriate for everyone.

Patients should discuss risks with a healthcare provider if they have:

  • History of pancreatitis
  • Gallbladder disease
  • Severe gastrointestinal disease
  • Kidney disease
  • Dehydration risk
  • Diabetes using insulin or sulfonylureas
  • Pregnancy or plans for pregnancy
  • Breastfeeding
  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2
  • Eating disorder history
  • Severe nausea or vomiting

FDA labeling for GLP-1 medications commonly includes warnings related to thyroid C-cell tumors observed in rodents, and patients should review product-specific prescribing information with their healthcare provider.

Unapproved incretin products

Patients should avoid unapproved online products marketed as semaglutide, tirzepatide, retatrutide, cagrilintide, or other research peptides. The FDA has warned about fraudulent compounded semaglutide and tirzepatide products marketed in the United States with false information on the label.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss(link). U.S. Food and Drug Administration.

How W8MD can help with incretin therapy

W8MD Weight Loss, Sleep and MedSpa can help eligible patients determine whether incretin therapy is appropriate for weight loss, obesity medicine, metabolic health, or diabetes-related needs.

W8MD may help with:

W8MD focus on weight loss first

Although incretin therapy is important in diabetes care, W8MD’s main focus is helping patients lose weight and maintain weight loss. This matters because weight loss may improve many weight-related health problems, including:

W8MD can also coordinate diabetes-related medication decisions with a patient’s primary care provider, endocrinologist, or other healthcare professionals when needed.

Affordable W8MD incretin and GLP-1 options

Affordable incretin and GLP-1 weight loss options

W8MD offers GLP-1 weight loss injections and related incretin therapy options such as Wegovy, Ozempic, Zepbound, Mounjaro, semaglutide, tirzepatide, and newer oral options when medically appropriate.

  • Affordable GLP-1 options starting at $29.99/week and up with insurance for visits for eligible patients.
  • Most insurances accepted for qualifying medical visits.
  • Self-pay GLP-1 injection options starting from $59.99/week and up when available and medically appropriate.
  • Pricing, insurance coverage, medication access, prior authorization, and eligibility vary by patient, location, medication, pharmacy availability, and medical evaluation.

W8MD locations

W8MD serves patients from New York City and Philadelphia offices, with service areas extending across the Northeast and Mid-Atlantic region.

Location Address Phone Services Map
Brooklyn / New York City Weight Loss Center 2632 E 21st Street, Suite L3, Brooklyn, NY 11235 (718) 946-5500 Medical weight loss, GLP-1 weight loss injections, sleep medicine, MedSpa, nutrition View map
Philadelphia / Greater Philadelphia Weight Loss Center 1718 Welsh Road, 2nd Floor, Suite C, Philadelphia, PA 19115 (215) 676-2334 Medical weight loss, GLP-1 weight loss injections, sleep medicine, nutrition, wellness services View map

Service areas

Who may benefit from incretin therapy?

Incretin therapy may be considered for eligible patients with:

Incretin therapy and maintenance

A major challenge after successful weight loss is preventing regain. Many patients need a maintenance plan after reaching goal weight or near-goal weight.

Maintenance strategies may include:

Frequently asked questions

What is incretin therapy?

Incretin therapy uses medications that mimic or enhance gut hormones such as GLP-1 and GIP to improve appetite control, satiety, insulin secretion, glucagon regulation, and blood sugar control.

Is incretin therapy mainly for weight loss or diabetes?

Historically, incretin therapy was mainly used for type 2 diabetes. Today, GLP-1 and related incretin medications are also major tools in medical weight loss and obesity medicine.

What is the difference between GLP-1 medications and DPP-4 inhibitors?

GLP-1 medications directly activate GLP-1 receptors and can produce significant weight loss. DPP-4 inhibitors prolong the body’s natural incretin hormones and mainly help with blood sugar control, usually without major weight loss.

Can W8MD help with incretin therapy for weight loss?

Yes. W8MD can evaluate eligible patients for incretin-based medical weight loss, including GLP-1 injections, oral options when appropriate, nutrition support, sleep apnea screening, and long-term maintenance.

Can incretin therapy help diabetes?

Yes. Incretin therapies can improve blood sugar control in type 2 diabetes. Patients with diabetes should use these medications under medical supervision, especially if they take insulin or sulfonylureas.

Are incretin medications safe?

They can be safe and effective for selected patients but require medical evaluation, correct dosing, monitoring for side effects, and attention to contraindications.

Is retatrutide available?

Retatrutide is investigational unless approved by regulatory authorities in the future. Patients should not buy unapproved research peptides online.

Does W8MD help with sleep apnea related to obesity?

Yes. W8MD can screen for sleep apnea, arrange home sleep testing when appropriate, and help eligible adults with obesity and moderate-to-severe OSA evaluate Zepbound when medically appropriate.

Conclusion

Incretin therapy has transformed the treatment of obesity, overweight, type 2 diabetes, and cardiometabolic risk. GLP-1 receptor agonists, dual GIP/GLP-1 agonists, oral GLP-1 medications, DPP-4 inhibitors, and emerging investigational agents all work through gut hormone pathways, but their effects on weight loss and blood sugar differ. For W8MD patients, incretin therapy is especially important as a tool for physician-supervised weight loss, appetite control, GLP-1 maintenance, sleep apnea risk reduction, and long-term health improvement. W8MD Weight Loss, Sleep and MedSpa can help eligible patients choose safe, evidence-based incretin options and combine them with nutrition, sleep care, and maintenance support.

See also

Relevant WikiMD links

Further reading

  • FDA Approves New Medication for Chronic Weight Management(link). U.S. Food and Drug Administration.November 8, 2023.
  • FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight(link). U.S. Food and Drug Administration.March 8, 2024.
  • FDA Approves First Medication for Obstructive Sleep Apnea(link). U.S. Food and Drug Administration.December 20, 2024.
  • Novel Drug Approvals for 2026(link). U.S. Food and Drug Administration.
  • FOUNDAYO orforglipron tablets prescribing information(link). U.S. Food and Drug Administration.
  • "Triple-Hormone-Receptor Agonist Retatrutide for Obesity".New England Journal of Medicine.2023;doi:10.1056/NEJMoa2301972.PMID:37366315.
  • "Cardiovascular safety of dipeptidyl peptidase-4 inhibitors".Current Cardiology Reports.2016;PMC:4891459.

External links


Retrieved from "https://w8md.com/w/index.php?title=Incretin_therapy&oldid=5946"